Roferon and (roferon a)
A ROFERON (Roferon A).
Recombinant? -2 A-interferon, sinteziruemy culture bacteria sticks.
For actions and testimony to the use of close to reaferonu.
Assign intramuscularly and subcutaneously.
In volosatokletochnom leukemia imposed on three million IU per day for 16-24 weeks; Supporting dose of 3 million IU three times a week.
When T-cell lymphoma in the first 3 days appoint 3000000 IU, 4-6 in the second day-to 9000000 IU, in the 7-84 th-on 18000000 IU; Supports up to 18 million doses ME 3 times a week.
In Kaposi sarcoma with HIV in the first three days to enter 3000000 IU, in 4
6-days - on 9000000 IU, 7-9 in the second on 18000000 IU; with good portability in the future (up to 84 days) dose increased to 36 million IU; supporting dose is no more than for 36 million IU three times a week.
In kidney cancer apply to 18 million-36 million IU per day for 84 days.
In melanome appoint 18 million IU three times a week for 8-12 months.
In chronic mieloleykoze imposed in the first three days of 3 million IU, 4-6 in the second day-to 6000000 IU and 7-84 th day-to 9 million IU per day.
In chronic active hepatitis in the use of 4.5 million IU three times a week for 6 months.
In chronic hepatitis C appoint 6 million IU three times a week for three months, followed by 3 million IU for another 3-9 months.
In meolomnoy diseases impose on 3 million IU three times a week, increasing the maximum weekly dose transferred (18000000 9000000-IU).
Possible side effects: "grippopodobny" syndrome, a violation of view, swelling, dizziness.
Contraindications: severe cardiovascular diseases in history, serious violations of blood, liver and kidney functions, arterial disease.
Form release: dried powder for injection solutions in vials on 3000000, 4500000, 6000000, 9000000 and 18000000 IU and syringe tyubikah on 3000000, 4500000, 6000000 and 9 000000 IU.
Storage: List B.
|
||
Materials allowed to copy only with the active hyperlink to the handbook of medicines
|
||
